Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVATE early low-dose prophylaxis in previously untreated hemophilia A patients
NL-OMON35535Phase 3Active, not recruiting
- Sponsor
- Baxter International Inc.
- Start
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Baxter International Inc. Primary endpoint: Incidence of inhibitor formation within first 50 exposure days. Started Sep 2012; status: active, not recruiting.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON35535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35535.